ECSP088531A - Vacuna terapéutica - Google Patents

Vacuna terapéutica

Info

Publication number
ECSP088531A
ECSP088531A EC2008008531A ECSP088531A ECSP088531A EC SP088531 A ECSP088531 A EC SP088531A EC 2008008531 A EC2008008531 A EC 2008008531A EC SP088531 A ECSP088531 A EC SP088531A EC SP088531 A ECSP088531 A EC SP088531A
Authority
EC
Ecuador
Prior art keywords
amyloidosis
diseases
amyloid
disorders
compositions
Prior art date
Application number
EC2008008531A
Other languages
English (en)
Inventor
Andrea Pfeifer
Claude Nicolau
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37836865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088531(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of ECSP088531A publication Critical patent/ECSP088531A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para uso terapéutico y diagnóstico en el tratamiento de enfermedades y trastornos causados por o asociados con amiloide o proteínas símil amiloide incluso amiloidosis.En particular, la presente invención provee nuevos métodos y composiciones para generar una altamente específica y altamente efectiva respuesta inmune en un organismo, pero particularmente dentro de un animal, particularmente un mamífero o un humano, capaz de prevenir o aliviar amiloidosis, o los síntomas asociados con amiloidosis, un grupo de enfermedades y trastornos asociados con formación de placa amiloide incluso amiloidosis secundaria y amiloidosis relacionada con la edad avanzada incluso, sin limitaciones, trastornos neurológicos tales como enfermedad de Alzheimer (AD), incluso enfermedades o condiciones caracterizados por la pérdida de la capacidad de memoria cognitiva tales como, por ejemplo, deterioro cognitivo leve (MCI).
EC2008008531A 2005-12-12 2008-06-12 Vacuna terapéutica ECSP088531A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05027091 2005-12-12
EP06009098 2006-05-02

Publications (1)

Publication Number Publication Date
ECSP088531A true ECSP088531A (es) 2008-07-30

Family

ID=37836865

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008531A ECSP088531A (es) 2005-12-12 2008-06-12 Vacuna terapéutica

Country Status (23)

Country Link
US (2) US7807175B2 (es)
EP (2) EP1959991B1 (es)
JP (2) JP5249043B2 (es)
KR (2) KR101236611B1 (es)
CN (1) CN101330923B (es)
AR (1) AR058327A1 (es)
AU (1) AU2006326283B2 (es)
BR (1) BRPI0619747B8 (es)
CA (1) CA2633399C (es)
CR (1) CR9994A (es)
DK (1) DK1959991T3 (es)
EC (1) ECSP088531A (es)
ES (2) ES2551604T3 (es)
IL (1) IL191397A (es)
MA (1) MA30252B1 (es)
MY (1) MY181173A (es)
NO (1) NO346055B1 (es)
NZ (1) NZ568384A (es)
RU (2) RU2440824C2 (es)
SG (1) SG172617A1 (es)
TW (1) TWI537000B (es)
WO (1) WO2007068411A2 (es)
ZA (1) ZA200804918B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX2009005279A (es) 2006-11-24 2009-05-28 Ac Immune Sa Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2106802A1 (en) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modified peptides as synthetic vaccines in amyloid-associated disease
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9283184B2 (en) 2008-11-24 2016-03-15 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
KR20120004994A (ko) 2009-03-18 2012-01-13 에이씨 이뮨 에스.에이. 치료적 이용 방법
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
KR100929372B1 (ko) * 2009-05-22 2009-12-02 고려대학교 산학협력단 아밀로이드 베타 단편을 유효성분으로 포함하는 돌연변이 ｓｏｄ1에 의한 ａｌｓ 예방 및 치료용 조성물
AT508638B1 (de) * 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
KR101790806B1 (ko) 2010-03-10 2017-11-20 프로비오드룩 아게 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
MX2012010810A (es) * 2010-03-19 2013-02-07 Massachusetts Inst Technology Composiciones de vesícula de lípido y métodos de uso.
US20110229556A1 (en) * 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
KR101851810B1 (ko) 2010-04-16 2018-04-26 에이씨 이뮨 에스.에이. 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 신규 화합물
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2603233A1 (en) 2010-08-12 2013-06-19 AC Immune S.A. Vaccine engineering
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
TW201223561A (en) 2010-10-26 2012-06-16 Ac Immune Sa Preparation of an antigenic construct
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
KR20160099732A (ko) * 2011-09-23 2016-08-22 에이씨 이뮨 에스.에이. 백신 요법
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
EP2970452A2 (en) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
EP4043036A1 (en) 2013-09-27 2022-08-17 Massachusetts Institute of Technology Carrier-free biologically-active protein nanostructures
WO2015095780A1 (en) * 2013-12-20 2015-06-25 The University Of Kansas Toll-like receptor 8 agonists
AR103162A1 (es) * 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
US11034752B2 (en) 2015-08-12 2021-06-15 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018081085A1 (en) * 2016-10-25 2018-05-03 The Regents Of The University Of California Methods of diagnosis and treatment of alzheimer's disease
WO2018204302A1 (en) 2017-05-01 2018-11-08 Vanderbilt University Phosphorylated hexaacyl disaccharides (phads) for treating or preventing infections
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
AR113792A1 (es) 2017-10-25 2020-06-10 Janssen Pharmaceuticals Inc Composiciones de péptidos tau fosforilados y sus usos
CN108037277A (zh) * 2017-12-07 2018-05-15 中国兽医药品监察所 一种区分牛布鲁氏菌疫苗免疫与自然感染状态的方法
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗
BR112020020660A2 (pt) * 2018-04-10 2021-03-02 Ac Immune Sa vacinas terapêuticas anti-abeta
CN113508127A (zh) 2018-11-06 2021-10-15 阿尔萨泰克公司 神经变性疾病的基于细胞的基因疗法
BR112021014794A2 (pt) 2019-02-08 2021-10-05 Ac Immune S.A. Método de administração segura de vacina de peptídeo de tau fosforilada
EP3965817A4 (en) 2019-04-24 2023-11-22 Janssen Pharmaceuticals, Inc. HETEROLOGICAL ADMINISTRATION OF TAU VACCINES
TW202110425A (zh) 2019-05-21 2021-03-16 瑞士商Ａｃ 免疫有限公司 抗Ａβ疫苗治療
WO2021207303A1 (en) * 2020-04-07 2021-10-14 Alsatech, Inc. Immune stimulation against coronavirus infections
EP4654990A1 (en) 2023-01-26 2025-12-03 AC Immune SA Anti-abeta vaccine therapy
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847082A (en) 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
WO2001039796A2 (en) * 1999-11-29 2001-06-07 Neurochem Inc. Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
DE10003992A1 (de) * 2000-01-29 2001-08-09 Bosch Gmbh Robert Sensoranordnung
AU2001290638C1 (en) * 2000-09-06 2009-04-30 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
CA2488230C (en) * 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates, and methods of use thereof
CA2511606A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
BRPI0410876B8 (pt) * 2003-06-02 2023-01-24 Evolutec Ltd composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão
US20050123553A1 (en) * 2003-07-30 2005-06-09 Alon Monsonego Amyloid beta-peptide and methods of use
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
MX358175B (es) * 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.

Also Published As

Publication number Publication date
AU2006326283B2 (en) 2012-01-19
BRPI0619747B1 (pt) 2019-03-26
AU2006326283A1 (en) 2007-06-21
ES2551604T3 (es) 2015-11-20
MA30252B1 (fr) 2009-03-02
DK1959991T3 (da) 2013-06-17
EP1959991B1 (en) 2013-03-20
AR058327A1 (es) 2008-01-30
RU2440824C2 (ru) 2012-01-27
EP1959991A2 (en) 2008-08-27
ZA200804918B (en) 2011-10-26
RU2011141308A (ru) 2013-04-20
KR101152557B1 (ko) 2012-09-07
CA2633399A1 (en) 2007-06-21
NZ568384A (en) 2011-09-30
BRPI0619747A2 (pt) 2011-10-18
US8603487B2 (en) 2013-12-10
MY181173A (en) 2020-12-21
TWI537000B (zh) 2016-06-11
RU2008128133A (ru) 2010-01-20
EP2380588B1 (en) 2015-08-05
JP5249043B2 (ja) 2013-07-31
TW200744630A (en) 2007-12-16
EP2380588A1 (en) 2011-10-26
BRPI0619747B8 (pt) 2021-05-25
KR20120061049A (ko) 2012-06-12
KR101236611B1 (ko) 2013-03-04
US20090238840A1 (en) 2009-09-24
CN101330923B (zh) 2015-01-07
JP2013126993A (ja) 2013-06-27
JP2009519915A (ja) 2009-05-21
NO346055B1 (no) 2022-01-24
CA2633399C (en) 2016-01-26
WO2007068411A3 (en) 2007-08-23
KR20080084830A (ko) 2008-09-19
NO20082216L (no) 2008-08-22
ES2407429T3 (es) 2013-06-12
SG172617A1 (en) 2011-07-28
US7807175B2 (en) 2010-10-05
CN101330923A (zh) 2008-12-24
US20080267986A1 (en) 2008-10-30
CR9994A (es) 2008-09-22
HK1127486A1 (en) 2009-09-25
WO2007068411A2 (en) 2007-06-21
IL191397A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
ECSP088531A (es) Vacuna terapéutica
AR058326A1 (es) Anticuerpo monoclonal
MX2011010353A (es) Composicion farmaceutica.
SV2008002511A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
UY27003A1 (es) Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2008060364A3 (en) Humani zed antibody against amyloid beta
MY164579A (en) Safe and functional humanized antibodies
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
CR20140496A (es) Anticuerpos humanizados contra beta-amiloides
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
UA102368C2 (ru) СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
EA201171352A1 (ru) Антигенсвязывающие фрагменты антитела и их применение для лечения или диагностики глазных болезней
WO2008070284A3 (en) Amyloid beta peptides and methods of uses thereof
TH92430B (th) วิธีการรักษาและองค์ประกอบของวัคซีน สำหรับการบำบัดโรคแอมีลอยด์
TH149012A (th) วิธีการรักษาและองค์ประกอบของวัคซีน สำหรับการบำบัดโรคแอมีลอยด์
PE20080455A1 (es) Mirtazapina para el tratamiento de dolor neuropatico
EP2404612A8 (en) Diagnosis, prophylaxis and therapy of Alzheimer's disease and other neurodementing disorders
Hahm P. 5. a. 005 An open label study of mirtazapine in the treatment of depression with Alzheimer's disease